Почетна › Немалоклетни карцином плућа › Вашингтон › Seattle
Kliničke studije za Немалоклетни карцином плућа u gradu Seattle, WA
55 studija za Немалоклетни карцином плућа traži učesnike na lokacijama u gradu Seattle i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.
Zvanični tekst studije (na engleskom)
Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Тражи се учесникФаза 1/2
- Virginia Mason Medical Center, Seattle
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Тражи се учесникФаза 3
- Swedish Medical Center-First Hill, Seattle
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
Тражи се учесникФаза 1
- Fred Hutchinson Cancer Research Center, Seattle
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Тражи се учесникФаза 1/2
- Virginia Mason Medical Center, Seattle
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
Тражи се учесникФаза 3
- Local Institution - 0283, Seattle
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Тражи се учесникФаза 3
- Swedish Cancer Institute ( Site 0143), Seattle
- St. Joseph Medical Center Hematology and Oncology - Silverdale ( Site 0192), Silverdale · 17 ми удаљено
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Тражи се учесникФаза 3
- Fred Hutchinson Cancer Center ( Site 3202), Seattle
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Тражи се учесникФаза 3
- Local Institution - 0508, Seattle
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
Тражи се учесникФаза 3
- Swedish Medical Center-First Hill, Seattle
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Тражи се учесникФаза 3
- Swedish Medical Center, Seattle
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Тражи се учесникФаза 1/2
- Fred Hutchinson Cancer Center, Seattle
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Тражи се учесникОпсервациона студија
- Swedish Medical Center-Ballard Campus, Seattle
- Kaiser Permanente Washington, Seattle
- Swedish Medical Center-First Hill, Seattle
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Тражи се учесникФаза 3
- Swedish Medical Center, Seattle
- VA Puget Sound Health Care System, Seattle
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Тражи се учесникФаза 2
- Fred Hutchinson Cancer Center, Seattle
- University of Washington Medical Center - Montlake, Seattle
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Тражи се учесникФаза 2
- Swedish Cancer Institute, Seattle
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Тражи се учесникФаза 3
- Research Site, Seattle
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Тражи се учесникОпсервациона студија
- Fred Hutchinson Cancer Center, Seattle
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Тражи се учесникФаза 2
- Research Site, Seattle
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Тражи се учесникФаза 2
- Swedish Cancer Institute, Seattle
- Swedish Medical Center, Seattle
T Cell Receptor T Cells for Advanced KRAS G12V-mutant Non-small Cell Lung Cancer, Pancreas Cancer, Colon Cancer
Тражи се учесникФаза 1
- Fred Hutch/University of Washington Cancer Consortium, Seattle
SMP-3124LP in Adults With Advanced Solid Tumors
Тражи се учесникФаза 1/2
- University of Washington, Seattle
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Тражи се учесникФаза 1/2
- Fred Hutchinson Cancer Research Center, Seattle
SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer
Тражи се учесникФаза 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Тражи се учесникФаза 2
- Swedish Medical Center-First Hill, Seattle
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Тражи се учесникФаза 2
- Swedish Medical Center-First Hill, Seattle
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Тражи се учесникФаза 1/2
- University of Washington Fred Hutchinson Cancer Center, Seattle
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Тражи се учесникФаза 2/3
- Fred Hutchinson Cancer Center. /ID# 277939, Seattle
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Тражи се учесникФаза 1/2
- University of Washington, Fred Hutchinson Cancer Center, Seattle
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Тражи се учесникФаза 1
- Fred Hutchinson Cancer Center, Seattle
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Тражи се учесникФаза 3
- University of Washington - Fred Hutchinson Cancer Center, Seattle
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Тражи се учесникФаза 1/2
- Swedish Medical Center, Seattle
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Тражи се учесникФаза 1
- University of Washington Fred Hutchinson, Seattle
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Тражи се учесникФаза 3
- Clinical Study Site, Seattle
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
Тражи се учесникФаза 2
- Fred Hutchison Cancer Center, Seattle
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
Тражи се учесникФаза 2
- University of Washington (Data Collection Only), Seattle
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Тражи се учесникФаза 1
- Fred Hutchinson Cancer Center, Seattle
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Тражи се учесникФаза 1
- Fred Hutchinson Cancer Center, Seattle
Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
Тражи се учесникФаза 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer
Тражи се учесник
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Тражи се учесникФаза 1
- Fred Hutchinson Cancer Center, Seattle
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Тражи се учесникФаза 1
- University Of Washington, Seattle
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
Тражи се учесникФаза 1
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Тражи се учесникФаза 1
- Swedish Cancer Institute, Seattle
- Swedish Medical Center, Seattle
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Тражи се учесникФаза 2
- Seattle Cancer Care Alliance, Seattle
Exercise Training for the Improvement of Immune Activity and Treatment Outcomes During Immunotherapy for Non-small Cell Lung Cancer, BOOST Trial
Тражи се учесник
- Fred Hutch/University of Washington Cancer Consortium, Seattle
SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer
Тражи се учесникФаза 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Тражи се учесникФаза 1/2
- Fred Hutchinson Cancer Center, Seattle
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Тражи се учесникФаза 2
- Fred Hutchinson Cancer Center, Seattle
- Swedish Medical Center-First Hill, Seattle
- FHCC at Northwest Hospital, Seattle
- и још 1
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Тражи се учесникФаза 1
- Fred Hutchinson Cancer Center, Seattle
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Тражи се учесникФаза 1/2
- Virginia Mason Medical Center, Seattle
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Тражи се учесникОпсервациона студија
- Massive Bio SYNERGY-AI site, Seattle
A Study of NX-1607 in Adults With Advanced Malignancies
Тражи се учесникФаза 1
- Fred Hutchinson Cancer Center, Seattle
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Тражи се учесникФаза 1/2
- Fred Hutch Cancer Center, Seattle
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
Тражи се учесникФаза 1
- Swedish Health Sciences, Seattle
- Research Site, Seattle
A Study of IBI363 in Subjects with Advanced Solid Malignancies
Тражи се учесникФаза 2
- Fred Hutchinson Cancer Center, Seattle
Studije za Немалоклетни карцином плућа u drugim gradovima
- Houston, TX143 студија
- New York City, NY123 студија
- Arlington, VA111 студија
- Nashville, TN97 студија
- Los Angeles, CA92 студија
- Boston, MA87 студија
- St. Louis, MO68 студија
- Baltimore, MD60 студија
- San Antonio, TX60 студија
- Chicago, IL59 студија
- Columbus, OH57 студија
- Washington, DC55 студија
Ostale studije u gradu Seattle
- Рак (све врсте)48 студија
- Рак простате45 студија
- Akutna mijeloidna leukemija40 студија
- Метастатски карцином39 студија
- Рак дојке37 студија
- Колоректални карцином35 студија
- Рак плућа34 студија
- Рак јајника29 студија
- Рак панкреаса22 студија
- Многи мијелом22 студија
- Akutna limfoblastna leukemija22 студија
- Hronična limfocitna leukemija22 студија
Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.